drugset
drugset / Trial / NCT06591845

Thorough QT/QTc (TQT) Clinical Study to Evaluate the Effects of Ziresovir on Cardiac Repolarization in Healthy Subjects

NCT06591845 ↗

Phase 1 Completed 34 enrolled Shanghai Ark Biopharmaceutical Co., Ltd.
RandomizedCrossoverSingle-blindTreatment

Summary

This is a single-center, randomized, partially double-blind, placebo and active-controlled, 4-period crossover design thorough QT/QTc (TQT) clinical study to evaluate the effects of ziresovir on cardiac repolarization in healthy subjects.

Timeline

Start
2024-09-25
Primary completion
2024-12-16
Completion
2024-12-23

Drugs

EvaluationDrugModalityDoseRoute
Comparator Moxifloxacin Small molecule 400 mg Oral
Subject Ziresovir Small molecule 125 mg Oral
Subject Ziresovir Small molecule 500 mg Oral

Indications

No indication recorded.